Cassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer’s Disease

Go back to Cassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer’s Disease
(NASDAQ: SAVA) Delayed: 41.43 -0.36 (0.86%)
Previous Close $41.79    52 Week High
Open $41.68    52 Week Low
Day High $43.18    P/E N/A 
Day Low $40.83    EPS
Volume 586,740